Last reviewed · How we verify
Miacalcin (calcitonin (salmon synthetic))
Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract.
At a glance
| Generic name | calcitonin (salmon synthetic) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Calcitonin [EPC] |
| Target | calcitonin receptors |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1978 |
Mechanism of action
Calcitonin salmon is a calcitonin receptor agonist that mainly influences bone, though it also affects the kidneys and gastrointestinal tract. Its actions are similar to mammalian calcitonins but are more potent and longer-lasting.
Approved indications
- Hypercalcemia Treatment Adjunct
- Osteitis deformans
- Postmenopausal osteoporosis
Common side effects
- nausea with or without vomiting
- injection site inflammation
- flushing of the face or hands
Drug interactions
- lithium
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Miacalcin CI brief — competitive landscape report
- Miacalcin updates RSS · CI watch RSS
- Sanofi portfolio CI